Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cue Biopharma Inc V.CUE


Primary Symbol: CUE

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.


NDAQ:CUE - Post by User

Post by nokiawatchon Mar 18, 2011 12:49pm
665 Views
Post# 18305964

CUE ON SALE

CUE ON SALE
 
 Japan's nuclear disaster will make the new generation of reactors safer, according to China's energy chief and to a leading builder, but neither suggested there would be any change to the timetable for building new plants….  China has only 10.8 gigawatts of nuclear generating capacity in operation after more than two decades of construction, so the plan to get almost four times as much underway in the next five years represents a dramatic acceleration.

  If Japan wins the fight to keep the levels of radiation under 100,000 microsieverts, can you even imagine the possible size of the rally in uranium?  Has that thought even occurred to most investors?  For every share panic-sold, one is panic-bought, by the pros. Panic time = loading up time!
 
 Its very true. The market does not care what share price you bought  for anything, even if its on sale at a discount price. Im betting the bottom is in, but  Im prepared to buy more if it goes even lower on a super sale.
 
GLTA   Due your DD
<< Previous
Bullboard Posts
Next >>